Cytos Biotech’s vaccine for allergic diseases has shown significant long-term efficacy in people who are allergic to house dust mites -- a common cause of sneezing, wheezing, eye inflammation and asthma; according to the Switzerland Company’s study results.
The intermediate-phase trial involving 20 patients, aged 18-56, with nose and eye symptoms and asthma caused by house dust mite allergy, evaluated the safety, tolerability and efficacy of a 10-week treatment with the vaccine, CYT005-AllQbG10, in conjunction with house dust mite allergen.
Cytos said the vaccine is believed to enhance the establishment of a so-called Th1 type immune response, which has been shown to suppress "allergic" Th2 type immune responses.
Well, this is indeed great news for dust-mite allergy sufferers that will have a long-term benefit...when and if the vaccine passes clinical trials and reaches the market. Read more at Allergizer and Reuters.
Comment Preview